Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Maravai LifeSciences Holdings paidMXN0 Mil more to buy back shares than it received from issuing new shares.
It spentMXN926 Mil paying down its debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0 Mil from paying cash dividends to shareholders.
It spentMXN70 Mil on other financial activities.
In all, Maravai LifeSciences HoldingsspentMXN996 Mil on financial activities for the
three
months ended in Mar. 2026.
Maravai LifeSciences Holdings (MEX:MRVI) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Maravai LifeSciences Holdings's issuance of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Maravai LifeSciences Holdings's repurchase of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Maravai LifeSciences Holdings's net issuance of debt for the
three
months ended in Mar. 2026 was MXN-926 Mil.
Maravai LifeSciences Holdings spentMXN926 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Maravai LifeSciences Holdings's net issuance of preferred for the
three
months ended in Mar. 2026 was MXN0 Mil.
Maravai LifeSciences Holdings paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Maravai LifeSciences Holdings's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN0 Mil.
Maravai LifeSciences Holdings receivedMXN0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Maravai LifeSciences Holdings's other financing for the
three
months ended in Mar. 2026 was MXN-70 Mil.
Maravai LifeSciences Holdings spentMXN70 Mil on other financial activities.
Maravai LifeSciences Holdings Cash Flow from Financing Related Terms
Maravai LifeSciences Holdings Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings Cash Flow from Financing Chart
Maravai LifeSciences Holdings Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,209 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN-1,209 Mil mean?
Maravai LifeSciences Holdings (MEX:MRVI) has a Cash Flow from Financing of MXN-1,209 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Maravai LifeSciences Holdings and its competitors.
Is Maravai LifeSciences Holdings' Cash Flow from Financing too high?
Maravai LifeSciences Holdings' current Cash Flow from Financing is MXN-1,209 Mil. Overall, Maravai LifeSciences Holdings has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Cash Flow from Financing compare to LBRX and AVTX?
Maravai LifeSciences Holdings' Cash Flow from Financing of MXN-1,209 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current Cash Flow from Financing is MXN-1,209 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current Cash Flow from Financing of MXN-1,209 Mil. The stock's GF Value™ is MXN50.91, compared to a current price of MXN85.00 — trading 67% above its estimated fair value. The current Cash Flow from Financing is MXN-1,209 Mil. Maravai LifeSciences Holdings' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current Cash Flow from Financing is MXN-1,209 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 67% above its estimated GF Value™ of MXN50.91.
Key valuation signals for MEX:MRVI:
Cash Flow from Financing: MXN-1,209 Mil
GF Value™: MXN50.91 vs. price of MXN85.00 (67% above fair value)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
61GF Score
Get the complete analysis for MEX:MRVI
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
